Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager

Newron Pharmaceuticals SpA

SIX:NWRN

Watchlist

Dividends

Discount Rate

Price: 7.66 CHF -3.04%

Market Cap: 145.9m CHF

Have any thoughts about
Newron Pharmaceuticals SpA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	Abbvie Inc NYSE:ABBV	Biotechnology
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Realty Income Corp NYSE:O	Real Estate
US	Walt Disney Co NYSE:DIS	Media
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 7.66 CHF

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

NWRN Alert

Newron Pharmaceuticals SpA

7.66

-0.24 (-3.04%)

52 Week Range	4.23 10.96
Price Target

We'll email you a reminder when the closing price reaches CHF.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	Abbvie Inc NYSE:ABBV	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Realty Income Corp NYSE:O	US
	Walt Disney Co NYSE:DIS	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Newron Pharmaceuticals SpA

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Newron Pharmaceuticals SpA.

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Newron Pharmaceuticals SpA.

Provide P/S
for Newron Pharmaceuticals SpA.

Provide P/E
for Newron Pharmaceuticals SpA.

Provide P/OCF
for Newron Pharmaceuticals SpA.

Provide P/FCFE
for Newron Pharmaceuticals SpA.

Provide P/B
for Newron Pharmaceuticals SpA.

Provide EV/S
for Newron Pharmaceuticals SpA.

Provide EV/GP
for Newron Pharmaceuticals SpA.

Provide EV/EBITDA
for Newron Pharmaceuticals SpA.

Provide EV/EBIT
for Newron Pharmaceuticals SpA.

Provide EV/OCF
for Newron Pharmaceuticals SpA.

Provide EV/FCFF
for Newron Pharmaceuticals SpA.

Provide EV/IC
for Newron Pharmaceuticals SpA.

Show me price targets
for Newron Pharmaceuticals SpA made by professional analysts.

What are the Revenue projections
for Newron Pharmaceuticals SpA?

How accurate were the past Revenue estimates
for Newron Pharmaceuticals SpA?

What are the Net Income projections
for Newron Pharmaceuticals SpA?

How accurate were the past Net Income estimates
for Newron Pharmaceuticals SpA?

What are the EPS projections
for Newron Pharmaceuticals SpA?

How accurate were the past EPS estimates
for Newron Pharmaceuticals SpA?

What are the EBIT projections
for Newron Pharmaceuticals SpA?

How accurate were the past EBIT estimates
for Newron Pharmaceuticals SpA?

Compare the revenue forecasts
for Newron Pharmaceuticals SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Newron Pharmaceuticals SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Newron Pharmaceuticals SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Newron Pharmaceuticals SpA compared to its peers.

Compare the P/E ratios
of Newron Pharmaceuticals SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Newron Pharmaceuticals SpA with its peers.

Analyze the financial leverage
of Newron Pharmaceuticals SpA compared to its main competitors.

Show all profitability ratios
for Newron Pharmaceuticals SpA.

Provide ROE
for Newron Pharmaceuticals SpA.

Provide ROA
for Newron Pharmaceuticals SpA.

Provide ROIC
for Newron Pharmaceuticals SpA.

Provide ROCE
for Newron Pharmaceuticals SpA.

Provide Gross Margin
for Newron Pharmaceuticals SpA.

Provide Operating Margin
for Newron Pharmaceuticals SpA.

Provide Net Margin
for Newron Pharmaceuticals SpA.

Provide FCF Margin
for Newron Pharmaceuticals SpA.

Show all solvency ratios
for Newron Pharmaceuticals SpA.

Provide D/E Ratio
for Newron Pharmaceuticals SpA.

Provide D/A Ratio
for Newron Pharmaceuticals SpA.

Provide Interest Coverage Ratio
for Newron Pharmaceuticals SpA.

Provide Altman Z-Score Ratio
for Newron Pharmaceuticals SpA.

Provide Quick Ratio
for Newron Pharmaceuticals SpA.

Provide Current Ratio
for Newron Pharmaceuticals SpA.

Provide Cash Ratio
for Newron Pharmaceuticals SpA.

What is the historical Revenue growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the historical Net Income growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the current Free Cash Flow
of Newron Pharmaceuticals SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Newron Pharmaceuticals SpA.

NWRN

Income Statement

Depreciation & Amortization

Newron Pharmaceuticals SpA
Depreciation & Amortization

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

Adjust for Inflation

Newron Pharmaceuticals SpA
Depreciation & Amortization Peer Comparison

Comparables:

REC

PRL

FCM

SHE

Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors

Company		Depreciation & Amortization	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Newron Pharmaceuticals SpA SIX:NWRN	Depreciation & Amortization -€201k	CAGR 3-Years 3%	CAGR 5-Years -34%	CAGR 10-Years N/A
	Recordati Industria Chimica e Farmaceutica SpA MIL:REC	Depreciation & Amortization N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
P	Pierrel SpA MIL:PRL	Depreciation & Amortization -€3.3m	CAGR 3-Years -44%	CAGR 5-Years -25%	CAGR 10-Years 2%
	Friulchem SpA MIL:FCM	Depreciation & Amortization -€860.9k	CAGR 3-Years 3%	CAGR 5-Years 1%	CAGR 10-Years N/A
	Shedir Pharma Srl Unipersonale MIL:SHE	Depreciation & Amortization -€3.9m	CAGR 3-Years -22%	CAGR 5-Years -25%	CAGR 10-Years N/A

What is Newron Pharmaceuticals SpA's Depreciation & Amortization?

Depreciation & Amortization
-201k EUR

Based on the financial report for Dec 31, 2023, Newron Pharmaceuticals SpA's Depreciation & Amortization amounts to -201k EUR.

What is Newron Pharmaceuticals SpA's Depreciation & Amortization growth rate?

Depreciation & Amortization CAGR 5Y
-34%

Over the last year, the Depreciation & Amortization growth was 0%. The average annual Depreciation & Amortization growth rates for Newron Pharmaceuticals SpA have been 3% over the past three years , -34% over the past five years .

Newron Pharmaceuticals SpA
SIX:NWRN

Newron Pharmaceuticals SpA
Depreciation & Amortization

Newron Pharmaceuticals SpA
Depreciation & Amortization Peer Comparison

Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors

See Also

What is Newron Pharmaceuticals SpA's Depreciation & Amortization?

Depreciation & Amortization
-201k EUR

What is Newron Pharmaceuticals SpA's Depreciation & Amortization growth rate?

Depreciation & Amortization CAGR 5Y
-34%

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA SIX:NWRN

Newron Pharmaceuticals SpA Depreciation & Amortization

Newron Pharmaceuticals SpA Depreciation & Amortization Peer Comparison

Competitive Depreciation & Amortization Analysis Latest Figures & CAGR of Competitors

See Also

What is Newron Pharmaceuticals SpA's Depreciation & Amortization? Depreciation & Amortization -201k EUR

What is Newron Pharmaceuticals SpA's Depreciation & Amortization growth rate? Depreciation & Amortization CAGR 5Y -34%

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA
SIX:NWRN

Newron Pharmaceuticals SpA
Depreciation & Amortization

Newron Pharmaceuticals SpA
Depreciation & Amortization Peer Comparison

Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors

What is Newron Pharmaceuticals SpA's Depreciation & Amortization?

Depreciation & Amortization
-201k EUR

What is Newron Pharmaceuticals SpA's Depreciation & Amortization growth rate?

Depreciation & Amortization CAGR 5Y
-34%